The agreement, signed through Shilpa Medicare’s wholly owned subsidiary Shilpa Biologicals Private Limited, targets one of the world’s most widely used immuno-oncology medicines
India-Japan joint venture now manufactures over 100 molecular biology reagents and enzymes, strengthening Make in India, enabling Indian research and supporting Takara Bio’s global R&D programs from India
The sector is poised to transition from being the pharmacy of the world to becoming a global innovation powerhouse, say industry leaders
Partnership expands Avantor India's filtration portfolio, providing researchers and laboratories with enhanced access to Sartorius' high-performance filter papers backed by nationwide distribution and technical support
Itvisma is designed to target the underlying genetic cause of SMA by replacing the faulty SMN1 gene
Injectable antipsychotic is therapeutically equivalent to Zyprexa IntraMuscular Injection; addresses a US market worth $25.4 million
The acquisition expands Lonza’s biologics platform with transferrin receptor-based blood-brain barrier technology, strengthening its capabilities to support the development and manufacturing of next-generation therapies
Targeting wider access to cancer immunotherapy
MIC-Lx is designed to overcome this challenge by training the immune system to accept a donor organ
The new centre marks a significant milestone in Merck's India operations, reinforcing the company's commitment to building a more connected, agile, and future-ready digital enterprise
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
This makes the company among few in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing, encompassing payload synthesis, linker development and manufacturing
Partnership with Duopharma Biotech covers human insulin, insulin glargine and insulin aspart, supporting diabetes care and medicine security in Malaysia
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The event is expected to bring together health and wellness enthusiasts for an afternoon of insights, learning and practical takeaways
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Subscribe To Our Newsletter & Stay Updated
